182 related articles for article (PubMed ID: 24727210)
1. Psychostimulants, antidepressants and neurokinin-1 receptor antagonists ('motor disinhibitors') have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD.
Stanford SC
Neuropharmacology; 2014 Dec; 87():9-18. PubMed ID: 24727210
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of L-type Ca(v) channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-Choice Serial Reaction-Time Task.
Dudley JA; Weir RK; Yan TC; Grabowska EM; Grimmé AJ; Amini S; Stephens DN; Hunt SP; Stanford SC
Neuropharmacology; 2013 Jan; 64():329-36. PubMed ID: 22884624
[TBL] [Abstract][Full Text] [Related]
3. Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder.
Yan TC; Hunt SP; Stanford SC
Neuropharmacology; 2009 Dec; 57(7-8):627-35. PubMed ID: 19748515
[TBL] [Abstract][Full Text] [Related]
4. The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: sex differences and implications for the treatment of attention deficit hyperactivity disorder.
Porter AJ; Pillidge K; Grabowska EM; Stanford SC
Eur Neuropsychopharmacol; 2015 Apr; 25(4):512-21. PubMed ID: 25703442
[TBL] [Abstract][Full Text] [Related]
5. Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.
Berridge CW; Devilbiss DM
Biol Psychiatry; 2011 Jun; 69(12):e101-11. PubMed ID: 20875636
[TBL] [Abstract][Full Text] [Related]
6. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
7. Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.
Pillidge K; Porter AJ; Young JW; Stanford SC
J Psychopharmacol; 2016 Sep; 30(9):837-47. PubMed ID: 27097734
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.
Mannangatti P; Sundaramurthy S; Ramamoorthy S; Jayanthi LD
Psychopharmacology (Berl); 2017 Feb; 234(4):695-705. PubMed ID: 28013351
[TBL] [Abstract][Full Text] [Related]
9. NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.
Yan TC; McQuillin A; Thapar A; Asherson P; Hunt SP; Stanford SC; Gurling H
J Psychopharmacol; 2010 Jan; 24(1):27-38. PubMed ID: 19204064
[TBL] [Abstract][Full Text] [Related]
10. Attention-Deficit/Hyperactivity Disorder.
Bokor G; Anderson PD
J Pharm Pract; 2014 Aug; 27(4):336-49. PubMed ID: 25092688
[TBL] [Abstract][Full Text] [Related]
11. The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.
Pillidge K; Porter AJ; Dudley JA; Tsai YC; Heal DJ; Stanford SC
Br J Pharmacol; 2014 Oct; 171(20):4785-96. PubMed ID: 25074741
[TBL] [Abstract][Full Text] [Related]
12. Behavioural effects of monoamine reuptake inhibitors on symptomatic domains in an animal model of attention-deficit/hyperactivity disorder.
Hiraide S; Ueno K; Yamaguchi T; Matsumoto M; Yanagawa Y; Yoshioka M; Togashi H
Pharmacol Biochem Behav; 2013 Apr; 105():89-97. PubMed ID: 23380523
[TBL] [Abstract][Full Text] [Related]
13. Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis.
Tsai SJ
Med Hypotheses; 2003 Jun; 60(6):849-51. PubMed ID: 12699711
[TBL] [Abstract][Full Text] [Related]
14. The influence of test experience and NK1 receptor antagonists on the performance of NK1R-/- and wild type mice in the 5-Choice Serial Reaction-Time Task.
Weir RK; Dudley JA; Yan TC; Grabowska EM; Peña-Oliver Y; Ripley TL; Stephens DN; Stanford SC; Hunt SP
J Psychopharmacol; 2014 Mar; 28(3):270-81. PubMed ID: 23845920
[TBL] [Abstract][Full Text] [Related]
15. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review.
Inan F; Brunt TM; Contrucci RR; Hondebrink L; Franssen EJF
Ther Drug Monit; 2020 Apr; 42(2):271-281. PubMed ID: 32022784
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
Adell A
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.
Faraone SV
Neurosci Biobehav Rev; 2018 Apr; 87():255-270. PubMed ID: 29428394
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs.
Rupniak NM; Carlson EJ; Webb JK; Harrison T; Porsolt RD; Roux S; de Felipe C; Hunt SP; Oates B; Wheeldon A
Behav Pharmacol; 2001 Nov; 12(6-7):497-508. PubMed ID: 11742144
[TBL] [Abstract][Full Text] [Related]
19. Neural activation during response inhibition in adult attention-deficit/hyperactivity disorder: preliminary findings on the effects of medication and symptom severity.
Congdon E; Altshuler LL; Mumford JA; Karlsgodt KH; Sabb FW; Ventura J; McGough JJ; London ED; Cannon TD; Bilder RM; Poldrack RA
Psychiatry Res; 2014 Apr; 222(1-2):17-28. PubMed ID: 24581734
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological treatment of attention-deficit/hyperactivity disorder in adults].
Rollini M; Baud P
Rev Med Suisse; 2008 Jul; 4(165):1638-43. PubMed ID: 18767289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
